Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026)
Intellia Therapeutics (NTLA) posted quarterly Profit After Tax of -$96.2 million for Q1 2026, up 15.5% year-over-year from -$83.3 million in Q1 2025, and little changed quarter-over-quarter from -$96.2 million in Q4 2025.
Intellia Therapeutics (NTLA) Profit After Tax (2015 - 2026) Analysis & Trends
Intellia Therapeutics (NTLA) has reported Profit After Tax for 12 consecutive years, with -$96.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax rose 15.5% year-over-year to -$96.2 million; the TTM figure through Mar 2026 stood at -$395.0 million (up 24.68% YoY), while the FY2025 annual figure was -$412.7 million, up 20.49% from the prior year.
- Profit After Tax steadied at -$96.2 million in Q1 2026 per NTLA's latest filing, from -$96.2 million in the prior quarter.
- Across five years, Profit After Tax topped out at -$96.2 million in Q4 2025 and bottomed at -$147.0 million in Q2 2024.
- Historically, Profit After Tax has averaged -$116.5 million across 5 years, with a median of -$113.4 million in 2022.
- Annual changes were most pronounced in 2022 — Profit After Tax tumbled 217.87% — and 2025, when it soared 31.11%.
- Intellia Therapeutics' Profit After Tax stood at -$113.4 million in 2022, then decreased by 15.38% to -$130.8 million in 2023, then decreased by 1.13% to -$132.3 million in 2024, then increased by 27.32% to -$96.2 million in 2025, then dropped by 0.06% to -$96.2 million in 2026.
- Business Quant data shows NTLA's Profit After Tax at -$96.2 million in Q1 2026, -$96.2 million in Q4 2025, and -$101.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Intellia Therapeutics | 1.67 Bn | 1.67 Bn | - | -107.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -107.42 Mn |
| Mar 31, 2026 | -96.23 Mn |
| Dec 31, 2025 | -96.17 Mn |
| Sep 30, 2025 | -101.32 Mn |
| Jun 30, 2025 | -101.26 Mn |
| Mar 31, 2025 | -113.88 Mn |
| Dec 31, 2024 | -132.32 Mn |
| Sep 30, 2024 | -131.26 Mn |
| Jun 30, 2024 | -146.98 Mn |
| Mar 31, 2024 | -107.44 Mn |
| Dec 31, 2023 | -130.85 Mn |
| Sep 30, 2023 | -121.93 Mn |
| Jun 30, 2023 | -123.68 Mn |
| Mar 31, 2023 | -103.13 Mn |
| Dec 31, 2022 | -113.41 Mn |
| Sep 30, 2022 | -113.23 Mn |
| Jun 30, 2022 | -100.68 Mn |
| Mar 31, 2022 | -146.87 Mn |
| Dec 31, 2021 | -81.24 Mn |
| Sep 30, 2021 | -71.81 Mn |